Inflection Biosciences
Inflection Biosciences is a preclinical-stage Dublin-based biopharmaceutical company founded in 2012 that develops first-in-class small-molecule dual-mechanism kinase inhibitors for cancer, autoimmune, and inflammatory diseases, partnering pipeline assets with larger pharmaceutical companies.
- Company typePrivate
- Founded2012
- HeadquartersBlackrock, Ireland
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Inflection Biosciences does
Inflection Biosciences Ltd is a preclinical-stage biopharmaceutical company founded in 2012 and headquartered in Dublin, Ireland. The company develops first-in-class small-molecule kinase inhibitors for the treatment of cancer, autoimmune and inflammatory diseases, built around a dual-mechanism chemistry platform that combines PIM kinase inhibition with PI3K and/or mTOR pathway blockade in single agents. The lead asset, IBL-202, is a dual PIM/PI3K inhibitor in pre-clinical development for aggressive B-cell malignancies, T-cell lymphoma and acute myeloid leukemia, supported by data showing ten-fold greater activity than existing PI3K inhibitors in CLL models and synergy with venetoclax in DLBCL. Additional programs include AUM302 (formerly IBL-302), a triple PIM/PI3K/mTOR inhibitor out-licensed to Singapore-based AUM Biosciences, and the IBL-100 series of selective pan-PIM kinase inhibitors targeting autoimmune and inflammatory indications including rheumatoid arthritis, IBD, psoriasis and lupus nephritis, with the IBL-100s sub-program licensed to Swiss biotech Mysthera Therapeutics and IBL-101 retained internally.
The company's core technology originates from an exclusive worldwide license agreement signed in June 2013 with the Spanish National Cancer Research Centre (CNIO), covering pan-PIM kinase inhibitors and multi-targeting kinase inhibitors combining PIM and PI3K/mTOR activity. Inflection has built a network of pre-clinical research collaborations with MD Anderson Cancer Center, Trinity College Dublin, the Royal College of Surgeons in Ireland (RCSI), the Multiple Myeloma Research Foundation (MMRF), the Trinity Biomedical Sciences Institute, Lund University and others, generating publications in journals such as the British Journal of Haematology, EMBO Molecular Medicine and the European Journal of Haematology.
Inflection operates an asset-light, capital-efficient business model that does not commercialize products directly. The company licenses pipeline programs to larger pharmaceutical partners who assume responsibility for clinical development, manufacturing and commercialization; in exchange Inflection receives upfront payments, development and commercialization milestones, and royalties on future sales. The company has raised approximately €1.2 million in disclosed equity financing across two rounds (June 2013 and March 2015) plus non-dilutive grants from Enterprise Ireland and EISMEA, and holds a minority equity stake in Mysthera Therapeutics acquired as part of the 2023 out-license. The company has 1-10 employees and does not currently generate commercial product revenue.
Inflection Biosciences firmographics
Firmographics- Name
- Inflection Biosciences
- Legal name
- Inflection Biosciences Ltd
- Website
- https://inflectionbio.com
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Inflection Biosciences is a preclinical-stage Dublin-based biopharmaceutical company founded in 2012 that develops first-in-class small-molecule dual-mechanism kinase inhibitors for cancer, autoimmune, and inflammatory diseases, partnering pipeline assets with larger pharmaceutical companies.
- Ownership category
- akta.pro rank
Inflection Biosciences industry classification
Industry- Product category
- Oncology Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)
- akta.pro secondary industry
- Immunology & Inflammation Pharmaceuticals (HLAIAAAD)
Keywords
Where Inflection Biosciences is headquartered
LocationHeadquarters
- HQ city
- Blackrock
- HQ country
- Ireland
- HQ region
- Europe
Offices1 record
Markets served
Inflection Biosciences business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Licensing Revenue: The company generates revenue through licensing agreements where partners receive exclusive worldwide rights to develop, manufacture and commercialize compounds. Inflection receives upfront payments, contingent milestone payments and royalties on future sales.
- Equity Financing: Raised capital through private investor rounds and government funding (Enterprise Ireland) to advance pipeline development.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels3 records
Inflection Biosciences product offering
Product offeringCore offering
Inflection Biosciences develops a pipeline of small-molecule, first-in-class kinase inhibitors for cancer and autoimmune/inflammatory diseases. The company in-licenses novel dual-mechanism inhibitor chemistry from academic research institutes, advances candidates through preclinical development with academic collaborators, and out-licenses programs to larger pharmaceutical and biotech partners for clinical development, manufacturing and commercialization in exchange for upfront fees, milestones and royalties.
Product overview
Inflection Biosciences is developing a pipeline of small molecule kinase inhibitors for the treatment of cancer, autoimmune, and inflammatory diseases. The pipeline comprises multiple distinct programs: IBL-202 is a first-in-class dual PIM/PI3K inhibitor for B-cell malignancies, T-cell lymphoma, and AML; AUM302 is a triple PIM/PI3K/mTOR inhibitor partnered with AUM Biosciences; and the IBL-100 series/IBL-101 are selective pan-PIM kinase inhibitors for autoimmune diseases, with IBL-100s partnered to Mysthera Therapeutics and IBL-101 in internal development.
Differentiator
Problem solved
Functional benefit
Brands
- IBL-202: First-in-class, dual PIM kinase and PI3K inhibitor in development for aggressive B-cell malignancies, T-cell lymphoma and acute myeloid leukemia.
- AUM302
- IBL-101
Products and services
- IBL-202 First-in-class dual PIM kinase and PI3K inhibitor in preclinical development for aggressive B-cell malignancies, T-cell lymphoma and acute myeloid leukemia; reported as approximately ten times more active than existing PI3K inhibitors in CLL models and synergistic with venetoclax in DLBCL.
- AUM302 (formerly IBL-302)
Quantifiable outcome
- IBL-202 shown to be ten times more active than existing PI3K inhibitors in models of CLL
- +2 more outcomes
Companies that use Inflection Biosciences
Customer profileSegments4 records
Ideal customer profiles2 records
Inflection Biosciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Inflection Biosciences partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered core, major and minor.
- Mysthera TherapeuticscoreLicensed exclusive worldwide rights to IBL-100s (selective PIM kinase inhibitors) for development to treat autoimmune diseases. Inflection received upfront payment, milestone payments, royalties and acquired minority shareholding.
- AUM BiosciencescoreGlobal development and commercialisation rights to AUM302 (formerly IBL-302) granted to AUM Biosciences, Singapore. AUM Biosciences now responsible for further development of the program.
- MD Anderson Cancer CentermajorResearch collaboration to explore effects of pipeline compounds including dual mechanism PIM/PI3K inhibitors in head and neck cancer. Led by Professors Xiuning Le and Maura Gillison.
- Trinity Biomedical Sciences Institute (TBSI)minorImmuno-oncology research collaboration with Adjuvant Research Group to explore immunotherapeutic properties of dual mechanism PIM/PI3K inhibitors. Led by Professor Ed Lavelle.
- RCSI (Royal College of Surgeons in Ireland)majorResearch collaboration to understand mechanisms of resistance to breast cancer therapies and examine potential new treatments. Led by Professor Bryan Hennessy. Supported by Enterprise Ireland Innovation Voucher.
- Multiple Myeloma Research Foundation (MMRF)majorCollaboration for pre-clinical testing of IBL-202 in multiple myeloma through MMRF's Translational Network of Excellence program.
- Trinity College DublinmajorResearch collaboration with Institute of Molecular Medicine to examine effectiveness of kinase inhibitors in treating cancer, particularly treatment-resistant solid tumors. Led by Dr. Kathy Gately. Funded by Enterprise Ireland Innovation Partnership Program.
- Spanish National Cancer Research Centre (CNIO)coreLicensed exclusive worldwide rights to develop and commercialize novel kinase inhibitors including pan-PIM kinase inhibitors and multi-targeting kinase inhibitors combining PIM and PI3K/mTOR activity.
- Lund University Cancer CentreminorResearch collaboration with Associate Professors Sofie Mohlin and Daniel Bexell resulting in neuroblastoma publication in EMBO Molecular Medicine.
- Thomas Jefferson UniversityminorPre-clinical collaboration generating data on IBL-202 and IBL-301 in pancreatic cancer models.
- University Medical Center GöttingenminorCollaboration with PD Dr. med. Raphael Koch generating pre-clinical data on IBL-202 in peripheral T-cell lymphoma.
Scale indicators2 records
Recent moves6 records
Expansion highlights5 records
Inflection Biosciences competitors and assessment
Company assessmentDirect peers
- AUM Biosciences: Singapore-based clinical-stage oncology biotech developing small molecule kinase inhibitors; licensed AUM302 (formerly IBL-302) from Inflection, making it both a direct partner and the most comparable peer in pipeline and stage.
- Mysthera Therapeutics: Swiss biotech founded in 2023 by former Inflection CEO Darren Cunningham; licensed the IBL-100s pan-PIM kinase inhibitor program from Inflection for autoimmune and inflammatory diseases, sharing therapeutic focus and management lineage.
- BerGenBio: Norwegian clinical-stage oncology biotech developing selective kinase inhibitors (e.g., AXL inhibitors) and led by Inflection CMO Murray Yule's former team prior to its 2017 Oslo IPO; comparable in kinase-inhibitor focus and small-cap European biotech profile.
- MethylGene: Canadian clinical-stage small molecule oncology company developing kinase and epigenetic inhibitors; comparable in stage, capital-light model and focus on targeted oncology therapeutics.
- Sierra Oncology: Small-cap clinical-stage oncology biotech (acquired by GSK in 2022) developing targeted small molecule therapies including kinase inhibitors; comparable in therapeutic focus and licensing-driven business model.
- Constellation Pharmaceuticals: Clinical-stage small molecule oncology company (acquired by MorphoSys in 2021) developing targeted therapies; comparable in stage, targeted oncology focus, and eventual exit via acquisition by a larger pharma partner.
Broad incumbents
- Astex Therapeutics: Cambridge, UK-based fragment-based small molecule oncology company (acquired by Otsuka); directly relevant as a former employer of Inflection's CMO and as a peer in structure-based small molecule oncology drug discovery.
- Blueprint Medicines: US-based clinical and commercial-stage precision medicine company developing kinase inhibitors for oncology and rare diseases; comparable in kinase-inhibitor platform and dual oncology/immunology therapeutic scope, but materially larger and more advanced.
- Mirati Therapeutics: Clinical and commercial-stage targeted oncology company (acquired by BMS in 2024) developing small molecule kinase inhibitors; comparable in targeted small molecule oncology focus though at significantly larger scale.
Emerging players
- Nimbus Therapeutics: US-based small molecule drug discovery company using computational chemistry to develop targeted therapies across oncology, immunology and metabolic disease; comparable in small molecule platform approach and dual therapeutic-area ambition.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks7 records
Key highlights7 records
Customer concentration
Inflection Biosciences social profiles
Digital presenceInflection Biosciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Inflection Biosciences leadership team
Management profileNumber of profiles
Profiles5 records
Inflection Biosciences subsidiaries and ownership
Company hierarchySubsidiaries1 record
Inflection Biosciences funding detail
Funding detailFunding overview
Funding rounds3 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Inflection Biosciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Inflection Biosciences
What does Inflection Biosciences do?
Inflection Biosciences develops a pipeline of small-molecule, first-in-class kinase inhibitors for cancer and autoimmune/inflammatory diseases. The company in-licenses novel dual-mechanism inhibitor chemistry from academic research institutes, advances candidates through preclinical development with academic collaborators, and out-licenses programs to larger pharmaceutical and biotech partners for clinical development, manufacturing and commercialization in exchange for upfront fees, milestones and royalties.
Is Inflection Biosciences a public or private company?
Inflection Biosciences is a private company. It is classified as venture growth investor backed and is currently operating.
When was Inflection Biosciences founded?
Inflection Biosciences was founded in 2012. It employs 1 to 10 people.
Where is Inflection Biosciences based?
Inflection Biosciences is headquartered in Blackrock, Ireland, in the Europe region.
How does Inflection Biosciences make money?
Two revenue lines are on record. Licensing Revenue is the primary driver. The others are equity Financing.
Who are Inflection Biosciences's main competitors?
Direct peers on record are AUM Biosciences, Mysthera Therapeutics, BerGenBio, MethylGene, Sierra Oncology and Constellation Pharmaceuticals. Broad incumbents are Astex Therapeutics, Blueprint Medicines and Mirati Therapeutics. Nimbus Therapeutics is listed as an emerging player.
Does Inflection Biosciences have an API?
No public API is recorded for Inflection Biosciences.
What industry is Inflection Biosciences in?
Inflection Biosciences's product category is Oncology Therapeutics. Its primary akta.pro industry code is HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals, with a secondary code of HLAIAAAD, Immunology & Inflammation Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2834.